prima biomed to list on nasdaq, page-29

I have been following PRR for some time and in doing my own basic research I found this article

http://www.genengnews.com/analysis-and-insight/what-comes-after-dendreon-s-provenge/77899342/

Now I am no scientist (that is my wifes' domain), however I do realise that companies like Prima rely heavily upon a 'slow, steady and thorough' process. We might call it Due-Dilligence.

Anyway the fall in sp since the last time I was involved has me interested again for the simple reasoning that as the article from 2010 outlines, this all constitutes a new paradigm in the treatments involved.

So fast-forwarding to this latest announcement, I opted to contact the company and upon asking when this listing is likely, I was given the simple answer (quote) " Relatively soon".

Make of this what you wish, but I doubt many biotechs listed anywhere in the world could see themselves involved in a new paradigm.

Like it or not I reckon exposure on the US markets beats the ASX any day. In this regard someone mentioned FMG and that OS investors can come to the ASX. I was there when it was about 50cents before going to $111. So where were the OS investors then?

I also found this of particular recent interest particularly as Prima gets a mention...

http://www.dailydoseequities.com/blog/2012/1/7/the-turnaround-in-dendrion-dndn-presents-at-jp-morgan-in-sfo.html

esp.